UBE2I and acute promyelocytic leukemia: As a control, we treated CHO-PML cells in parallel with arsenic trioxide (As2O3), a drug successfully used to treat APL, which promotes PML multimerization and SUMOylation through Ubc9 recruitment to PML NBs (9, 30, 42, 43; reviewed in reference 44).